Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Denmark
/
Pharmaceuticals & Biotech
Create a narrative
Bavarian Nordic Community
CPSE:BAVA Community
1
Narratives
written by author
0
Comments
on narratives written by author
35
Fair Values set
on narratives written by author
Create a narrative
Bavarian Nordic
Popular
Undervalued
Overvalued
Community Investing Ideas
Bavarian Nordic
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues
Key Takeaways Expansion in public preparedness and successful vaccine launches could significantly enhance revenue streams through government contracts and new territories. Advancements in new vaccine candidates indicate promising pipeline potential, supporting future revenue growth and market expansion.
View narrative
DKK 270.50
FV
43.6% undervalued
intrinsic discount
0.78%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
28
users have followed this narrative
Updated
narrative
Your Valuation for
BAVA
BAVA
Bavarian Nordic
Your Fair Value
DKK
Current Price
DKK 152.55
87.2% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-465m
7b
2015
2018
2021
2024
2025
2027
2030
Revenue DKK 5.4b
Earnings DKK 941.8m
Advanced
Set Fair Value